Ismail Nermeen M, El-Deeb Ayman H, Emara Mohamed M, Tawfik Hoda I, Wanis Nabil Abdel, Hussein Hussein A
Department of Newcastle Disease, Veterinary Serum and Vaccine Research Institute, Abbassia, Cairo, Egypt.
2Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211 Egypt.
Virusdisease. 2018 Sep;29(3):324-332. doi: 10.1007/s13337-018-0463-3. Epub 2018 Jun 26.
In the present study, we carried-out assessment of efficacy of different immunization strategies using two bivalent vaccine formulations containing antigens of inactivated Newcastle disease virus (NDV-genotype VIId) and reassortant highly pathogenic avian influenza virus (H5N1-HPAIV) mixed with Montanide ISA71 and Montanide Gel02 as adjuvants. The efficacy of the prepared vaccines was evaluated by determining the cellular and humoral immune responses. In addition, protection against H5N1-AIV and NDV-genotype VIId challenge viruses post vaccination was assessed when Montanide-Gel02 based vaccine was inoculated in 10-days-old specific pathogen free chicks intraocularly once, twice or once followed by a boost with the Montanide ISA71 based vaccine. The cytokines profile analysis demonstrated that the prime-boost strategy induced the highest up-regulation in interferon-gamma (11.39-fold change) and interleukin-6 (14.12-fold change) genes expression. Also, enhanced lymphocytes proliferation was recorded beside increased antibody titers with protection levels reaching 50 and 60% against H5N1 and NDV challenge; respectively. Immunization with Montanide ISA71 inactivated vaccine induced 80% protection; however, the prime-boost combination afforded complete protection (100%) in the challenged chickens against mortality, clinical signs and virus shedding. Finally, these results highlight the significance of considering not only different vaccine platforms but also vaccination strategies to maximize protection against AIV and NDV with regards to the longevity of the vaccine-induced immune response.
在本研究中,我们使用两种二价疫苗制剂进行了不同免疫策略的效果评估,这两种制剂包含与Montanide ISA71和Montanide Gel02作为佐剂混合的灭活新城疫病毒(NDV - 基因型VIId)和重组高致病性禽流感病毒(H5N1 - HPAIV)的抗原。通过测定细胞免疫和体液免疫反应来评估所制备疫苗的效果。此外,当基于Montanide - Gel02的疫苗在10日龄无特定病原体雏鸡中进行一次、两次眼内接种或一次眼内接种后再用基于Montanide ISA71的疫苗进行加强免疫时,评估接种疫苗后对H5N1 - AIV和NDV - 基因型VIId攻击病毒的保护作用。细胞因子谱分析表明,初免 - 加强策略诱导干扰素 - γ(11.39倍变化)和白细胞介素 - 6(14.12倍变化)基因表达的上调最高。此外,除了抗体滴度增加外,淋巴细胞增殖也增强,对H5N1和NDV攻击的保护水平分别达到50%和60%。用Montanide ISA71灭活疫苗免疫诱导了80%的保护;然而,初免 - 加强组合在受攻击的鸡中提供了完全保护(100%),防止死亡、临床症状和病毒脱落。最后,这些结果强调了不仅要考虑不同的疫苗平台,还要考虑免疫策略的重要性,以便在疫苗诱导的免疫反应持续时间方面最大限度地提高对AIV和NDV的保护。